证券代码：600351 证券简称：亚宝药业 公告编号：2025-042 亚宝药业集团股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/26，由董事会提议 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2025 5 11 | 16 | 日~2025 | 年 | 月 | 14 | 日 | | 预计回购金额 | 0.5亿元~1亿元 | | | | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 8,000,000股 | | | | | | | | 累计已回购股数占总股本比例 | 1.14% | | | | | | | | 累计已回购金额 | 52 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●截至本公告日，亚宝药业集团股份有限公司（以下简称"公司"）控股股 东山西亚宝投资集团有限公司（以下简称"亚宝投资"）持有本公司股份94,300,000 股，占公司总股本的13.47%；亚宝投资所持有的公司股份累计质押股份数为 26,850,000股，占其持有公司股份总数的28.47%，占公司总股本的3.84%。 公司于2025年11月2日接到控股股东亚宝投资关于进行股票质押式回购交易 的通知，现将相关情况公告如下： 证券代码：600351 证券简称：亚宝药业 公告编号：2025-041 亚宝药业集团股份有限公司 关于控股股东进行股票质押式回购交易的公告 截至公告披露日，亚宝投资及其一致行动人累计质押股份情况如下： | 已质押股份情 | 未质押股份情 | 占公 | 本次质押前 | 本次质押后 | 占其所 | 况 | 况 | 持股比 | 司总 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | -- ...

Core Viewpoint - The company plans to repurchase shares starting from May 16, 2025, with an estimated amount of 50 million to 100 million yuan aimed at reducing registered capital [1] Group 1 - As of October 31, the company has repurchased a total of 8 million shares, accounting for 1.14% of the total share capital [1] - The total amount paid for the repurchased shares is 52.1519 million yuan, with a repurchase price range of 6.30 yuan to 6.65 yuan per share [1] - The company will implement the repurchase at its discretion during the repurchase period and will disclose progress in a timely manner [1]

Group 1 - The company has approved a share repurchase plan at the 2024 annual shareholders' meeting, with a total repurchase fund of no less than RMB 50 million and no more than RMB 100 million, at a maximum price of RMB 6.95 per share [1] - The repurchase period is set for a maximum of 6 months from the date of approval, with funds sourced from the company's own and raised funds [1] - As of October 30, 2025, the company has repurchased 8,000,000 shares, accounting for 1.14% of the total share capital, with a total payment of RMB 52,151,912, at a maximum price of RMB 6.65 and a minimum price of RMB 6.30 per share [1] Group 2 - The company will adhere to relevant regulations during the repurchase period and will make repurchase decisions based on market conditions, ensuring timely information disclosure regarding the progress of the share repurchase [2]

Group 1 - The core point of the article is that Yabao Pharmaceutical (600351) announced a share buyback program, having repurchased a total of 8,000,000 shares, which represents 1.14% of the company's total share capital as of October 30, 2025 [1]

Core Viewpoint - Yabao Pharmaceutical (600351.SH) has repurchased a total of 8 million shares, representing 1.14% of the company's total share capital, with a total expenditure of RMB 52.15 million as of October 30, 2025 [1] Summary by Relevant Sections - **Share Repurchase Details** - The company has conducted a share repurchase through centralized bidding [1] - The highest transaction price was RMB 6.65 per share, while the lowest was RMB 6.30 per share [1] - The total amount paid for the repurchase, excluding transaction fees, is RMB 52.15 million [1]

Core Viewpoint - Yabao Pharmaceutical (600351.SH) has repurchased a total of 8 million shares, representing 1.14% of the company's total share capital, with a total expenditure of RMB 52.15 million as of October 30, 2025 [1] Summary by Category - **Share Repurchase Details** - The company has conducted share repurchases through centralized bidding [1] - The highest transaction price for the repurchased shares was RMB 6.65 per share, while the lowest was RMB 6.30 per share [1] - The total amount paid for the repurchase, excluding transaction fees, was RMB 52.15 million [1]

证券代码：600351 证券简称：亚宝药业 公告编号：2025-040 亚宝药业集团股份有限公司 关于回购股份比例达到 1%暨回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/26，由董事会提议 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 月 2025 5 16 11 | 日~2025 | 年 | 14 | 日 | | 预计回购金额 | 0.5亿元~1亿元 | | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | 累计已回购股数 | □为维护公司价值及股东权益 8,000,000股 | | | | | | 累计已回购股数占总股本比例 | 1.14% | | | | | | 累计已回购金额 | 52,151,912.00元 | | | | | | 实际回购价格区间 | 6.30元/股~6.65元/股 | ...

Core Viewpoint - Yabao Pharmaceutical (600351.SH) reported its Q3 2025 results, highlighting a decrease in institutional ownership and changes in public fund holdings [1] Group 1: Institutional Investors - As of October 24, 2025, six institutional investors disclosed holdings in Yabao Pharmaceutical, totaling 144 million shares, which represents 20.63% of the company's total equity [1] - The institutional ownership decreased by 3.27 percentage points compared to the previous quarter [1] Group 2: Public Funds - One public fund, Huatai-PineBridge CSI Traditional Chinese Medicine ETF, increased its holdings by 0.16% compared to the last period [1] - A total of 91 public funds did not disclose their holdings this quarter, including various ETFs and mixed funds [1]

Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, and assumes legal responsibility for any false records or misleading statements [2][8][17] Financial Data - The third-quarter financial statements are unaudited, covering the period from the beginning to the end of the quarter [3][8] - The report includes significant non-recurring gains and losses, but specific amounts are not detailed in the provided documents [4] Shareholder Information - As of the end of the reporting period, the company has a total of 700,000,046 shares, with 6,000,000 shares (0.86%) held in a repurchase account [6] Board Meeting Resolutions - The company's board of directors approved the third-quarter report with unanimous support [8][11] - The board also approved revisions to the company's information disclosure system and management systems for shares held by directors and senior management [11][12][14]